VCEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vericel Corp (VCEL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive revenue growth, and solid earnings beat in Q4 2025, coupled with a Buy rating from analysts, make it an attractive option. While insider selling and neutral hedge fund activity are notable, they do not outweigh the positive catalysts for long-term growth.
The MACD is positive at 0.232, indicating bullish momentum, though it is contracting. RSI is neutral at 56.542, suggesting no overbought or oversold conditions. The stock is trading near its R1 resistance level of 38.639, with a pre-market price of 37.68, indicating potential upward movement. Moving averages are converging, signaling a potential trend change.
Q4 2025 revenue growth of 23.2% YoY, exceeding market expectations.
Net income and EPS growth of 17.35% and 21.21% YoY, respectively.
Gross margin improvement to 78.7%.
Analyst maintains a Buy rating with a price target of $45, indicating upside potential.
Insider selling has increased by 113.61% over the last month.
Hedge funds remain neutral with no significant trading trends.
No recent congress trading data or valuation metrics available.
In Q4 2025, Vericel reported revenue of $92.9 million, up 23.27% YoY, net income of $23.24 million, up 17.35% YoY, and EPS of $0.45, up 21.21% YoY. Gross margin improved to 78.7%, reflecting strong operational efficiency.
Truist analyst Richard Newitter maintains a Buy rating with a reduced price target of $45 (from $50), citing a positive outlook for the MedTech sector in 2026 and Vericel's durable revenue acceleration potential.
